

**UNITED STATES DISTRICT COURT  
SOUTHERN DISTRICT OF NEW YORK**

ESPERION THERAPEUTICS, INC.

Plaintiff,

v.

DAIICHI SANKYO EUROPE GMBH.,

Defendant.

Civil Action No:

**RULE 7.1 CORPORATE DISCLOSURE STATEMENT**

Plaintiff Esperion Therapeutics, Inc. (“Esperion”) through its undersigned counsel and pursuant to Federal Rule of Civil Procedure 7.1 and applicable local rules, submits this corporate disclosure statement identifying all of its publicly held parent corporations and all publicly held companies that directly or indirectly own, control or hold, with power to vote, ten percent or more of Esperion’s outstanding voting securities. Regarding the foregoing, Esperion represents as follows, to the best of its knowledge, information, and belief that Esperion is a Delaware corporation that has no parent corporation and is not aware of any publicly held corporation that holds 10% or more of the stock of Esperion.

Dated: March 27, 2023

Respectfully submitted,

ESPERION THERAPEUTICS, INC.,

By its attorneys,

/s/ Jordan D. Weiss

Jordan D. Weiss

Emily S. Unger (*pro hac vice* forthcoming)

Goodwin Procter LLP

The New York Times Building

620 Eighth Avenue

New York, NY 10018

(212) 813-8800

JWeiss@goodwinlaw.com

EUnger@goodwinlaw.com